Total for the last 12 months
number of access : ?
number of downloads : ?
ID 111302
Author
Yuasa, Shino The University of Tokushima
Yamaguchi, Harutaka The University of Tokushima KAKEN Search Researchers
Nakanishi, Yoshinori The University of Tokushima
Kawaminami, Shingo The University of Tokushima
Tabata, Ryo The University of Tokushima KAKEN Search Researchers
Shimizu, Nobuhiko The University of Tokushima
Kohno, Mitsuhiro The University of Tokushima
Shimizu, Teruki Toyo Hospital
Miyata, Junya Miyoshi Municipal Mino Hospital
Nakayama, Mayuko Hanoura Hospital of Orthopedics and Internal Medicine
Kishi, Jun The University of Tokushima KAKEN Search Researchers
Toyoda, Yuko The University of Tokushima KAKEN Search Researchers
Tani, Kenji The University of Tokushima KAKEN Search Researchers
Keywords
rheumatoid arthritis
biological agents
predictors
DAS28
Content Type
Journal Article
Description
Biological agents represent an important advancement in for the treatment of rheumatoid arthritis (RA), but there is a subset of patients who do not improve despite therapy. This study aimed to determine the efficacy of biological agents for RA and to identify clinical factors that are associated with their response. We studied 98 patients with RA who started an initiating biological agent which was selected from infliximab, etanercept, adalimumab and tociliximab at 4 medical institutions. Etanercept was the most frequently used biological agent followed by infliximab although there was a difference in the selection of the biological agents among medical institutions. We found that etanercept achieved the highest treatment response, remission rate and drug survival rate. A high disease activity in the baseline disease activity score-c-reactive protein (CRP) was shown to be a negative predictor of the treatment response, and high patient global assessment was significantly less likely to achieve a good response. At week 4, decreases in 28 swollen joint counts and CRP were useful as predictors for sustaining the efficacy up to week 48. These data demonstrate that assessments of the disease activity at baseline and the early treatment response may be useful in predicting the efficacy and drug survival rate of biological agents.
Journal Title
The Journal of Medical Investigation
ISSN
13496867
13431420
NCID
AA11166929
AA12022913
Publisher
Faculty of Medicine Tokushima University
Volume
60
Issue
1-2
Start Page
77
End Page
90
Sort Key
77
Published Date
2013-02
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences
University Hospital